Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/12/2009

ROCKVILLE, Md., March 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three months and twelve months ended December 31, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

For fiscal year 2008, revenues were $7.5 million versus $7.4 million for 2007. For the year ended December 31, 2008, the Company reported a net loss of ($24.9 million) or ($0.29) per share, versus ($23.4 million), or ($0.28) per share, for fiscal year 2007. As of December 31, 2008, the Company had cash and short-term investments of approximately $24 million.

Revenues for the fourth quarter ended December 31, 2008 were $4.0 million compared to $3.9 million for the fourth quarter ended December 31, 2007. The Company reported a net loss of ($2.8 million), or ($.04) per share for the three months ended December 31, 2008. This compares with a net loss of ($4.0 million), or ($0.05) per share for the fourth quarter 2007.

Kathy R. Wehmeir-Davis, Principal Accounting Officer, commented, "Financial results for 2008 are reflective of the Company's decision to realign its financial and human resources to focus primarily on the clinical development of our Aurora A and angiogenic kinase inhibitor, ENMD-2076, for the treatment of cancer. As a result of the realignment, the Company reduced its workforce by approximately sixty percent, which resulted in a fourth quarter charge for severance and related benefits of approximately $1.7 million. Our fourth quarter 2008 revenue was consistent with fourth quarter revenue in 2007."

Ms. Wehmeir-Davis continued, "For 2008, we recorded $7.5 million in royalty revenue from Celgene's sales of Thalomid(R), a small increase over our 2007 royalty revenues of $7.4 million. Research and development expenses decreased in 2008 by approximately $3.7 million, which results primarily from discontinuing clinical development of 2ME2 (Panzem(R) NCD) for oncology and winding down of manufacturing and clinical trial operations with our other product candidates. Also reflected in the operating results for 2008 is a non-cash charge of $2.0 million, which represents a purchase price adjustment milestone triggered by the dosing of the first patient in a clinical trial for ENMD-2076, which was paid in stock to Miikana shareholders. In 2009, we expect our revenues will remain consistent with 2008 and our cash expenses will decrease significantly compared to 2008 as we focus primarily on the development of ENMD-2076."

Executive Chairman of the Board, Michael M. Tarnow commented, "We ended 2008 on solid financial footing and continue to make progress on the implementation of our realigned strategy, which focuses specifically on the clinical development of our priority program, ENMD-2076. The Board remains confident that we have the right team in place to execute on this accelerated development strategy and the financial resources to accomplish our current and planned operational objectives well into 2010. We will continue to curtail all costs not associated with the development of ENMD-2076 in order to further preserve our financial resources."

In lieu of a fourth quarter and year end update call, up-to-date information regarding the Company, including our most recent Form 10-K filing and Letter from the Executive Chairman, can be found on our web site at www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company focusing primarily on the development of its priority program, ENMD-2076, for the treatment of cancer. ENMD-2076 is an Aurora A and angiogenic kinase inhibitor, which is currently in Phase 1 studies in patients with solid tumors and multiple myeloma. In addition, multiple Phase 1 and 2 clinical trials are ongoing for MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, and ENMD-1198, a novel tubulin-binding agent. The Company also has an approved IND application for Panzem(R) in the treatment of rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks patent, product liability, supply, competition relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, and other risks).

    CONTACT:
    Ginny Dunn
    Associate Director, Corporate
    Communications & Investor Relations
    EntreMed, Inc.
    240-864-2643

                                 ENTREMED, INC.
                          SUMMARY OF OPERATING RESULTS
                               Three Months Ended
                                  December 31,

                                             2008             2007

    Total revenues                      $  3,975,912     $  3,875,392

    Research and development            $  3,440,102     $  5,650,152

    General and administrative          $  2,489,947     $  1,978,982

    Net loss                            $ (2,547,552)    $ (3,767,496)

    Dividend on Series A
     convertible preferred stock        $   (251,250)    $   (251,250)

    Net loss attributable
     to common shareholders             $ (2,798,802)    $ (4,018,746)

    Net loss per share attributable to
     common shareholders
     (basic and diluted)                $      (0.04)    $      (0.05)

    Weighted average number of
     shares outstanding
     (basic and diluted)                  87,728,644       84,362,710



                            Twelve Months Ended
                                December 31,

                                             2008              2007

    Total revenues                     $   7,477,219     $   7,395,651

    Research and development           $  20,069,229     $  23,739,392

    General and administrative         $   7,764,532     $   7,386,570

    Acquired in-process R&D            $   2,000,000     $           -

    Net loss                           $ (23,862,028)    $ (22,411,121)

    Dividend on Series A
     convertible preferred stock       $  (1,005,000)    $  (1,005,000)

    Net loss attributable to
     common shareholders               $ (24,867,028)    $ (23,416,121)

    Net loss per share attributable to
     common shareholders
     (basic and diluted)               $       (0.29)    $       (0.28)

    Weighted average number of
     shares outstanding
     (basic and diluted)                  86,479,768        84,166,552

    Cash and Short-term Investments    $  24,291,173     $  47,748,191


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Rock, AR (PRWEB) , ... October 13, 2017 ... ... firm with locations throughout Arkansas that offers insurance and financial preparation services, is ... benefit the Rock City Rescue organization. , Rock City Rescue is a locally ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
Breaking Medicine Technology: